Literature DB >> 31882498

Clinical Implication of Pre-operative C-reactive Protein-Albumin Ratio as a Prognostic Factor of Patients With Pancreatic Ductal Adenocarcinoma: A Single-institutional Retrospective Study.

Masaaki Murakawa1, Naoto Yamamoto2, Yuto Kamioka2, Mariko Kamiya2, Satoshi Kobayashi3, Makoto Ueno3, Manabu Morimoto3, Yosuke Atsumi4, Toru Aoyama4, Hiroshi Tamagawa4, Norio Yukawa4, Yasushi Rino4, Munetaka Masuda4, Soichiro Morinaga2.   

Abstract

BACKGROUND: The C-reactive protein (CRP)-to-serum albumin ratio is associated with a poor prognosis in patients with several cancers. The purpose of this study was to clarify the relationship between the preoperative CRP/Alb ratio and overall survival of pancreatic ductal adenocarcinoma (PDAC) in patients who received radical surgery and S-1 adjuvant chemotherapy. PATIENTS AND METHODS: We included 117 patients who underwent radical surgery with S-1 adjuvant chemotherapy. We constructed receiver operating characteristic curve (ROC curve) of the CRP/Alb ratio to determine the cut-off value. We analyzed the relationship among the CRP/Alb ratio, clinicopathological status, and survival.
RESULTS: The optimal cut-off value of the CRP/Alb ratio was 0.036. All patients were divided into a high-ratio group (CRP/Alb ratio ≥0.036) and low-ratio group (CRP/Alb ratio <0.036). The 5-year overall survival (OS) rates in the high- and low-ratio groups were 22.5% and 36.4%, respectively (p=0.0089). The 5-year disease-free survival (DFS) rates in the high- and low-ratio groups were 12.5% and 22.1%, respectively (p=0.0097). The univariate and multivariate analyses of the OS showed that the pathological N factor and CRP/Alb ratio were independent factors of the survival. The univariate and multivariate analyses of the RFS showed that the pathological N factor, resection margin, and CRP/Alb ratio were independent factors of the survival.
CONCLUSION: The preoperative CRP/Alb ratio is a strong prognostic factor for PDAC patients with undergo curative resection with S-1 adjuvant chemotherapy. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  CRP/Alb ratio; Pancreatic ductal adenocarcinoma; prognostic factor

Mesh:

Substances:

Year:  2020        PMID: 31882498      PMCID: PMC6984104          DOI: 10.21873/invivo.11780

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  19 in total

1.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.

Authors:  Lola Rahib; Benjamin D Smith; Rhonda Aizenberg; Allison B Rosenzweig; Julie M Fleshman; Lynn M Matrisian
Journal:  Cancer Res       Date:  2014-06-01       Impact factor: 12.701

2.  The C-reactive Protein to Albumin Ratio Predicts Long-Term Outcomes in Patients with Pancreatic Cancer After Pancreatic Resection.

Authors:  Koichiro Haruki; Hiroaki Shiba; Yoshihiro Shirai; Takashi Horiuchi; Ryota Iwase; Yuki Fujiwara; Kenei Furukawa; Takeyuki Misawa; Katsuhiko Yanaga
Journal:  World J Surg       Date:  2016-09       Impact factor: 3.352

3.  Clinical usefulness of postoperative C-reactive protein/albumin ratio in pancreatic ductal adenocarcinoma.

Authors:  Kota Arima; Yo-Ichi Yamashita; Daisuke Hashimoto; Shigeki Nakagawa; Naoki Umezaki; Takanobu Yamao; Masayo Tsukamoto; Yuki Kitano; Kensuke Yamamura; Tatsunori Miyata; Hirohisa Okabe; Takatsugu Ishimoto; Katsunori Imai; Akira Chikamoto; Hideo Baba
Journal:  Am J Surg       Date:  2017-08-26       Impact factor: 2.565

4.  Cancer statistics, 2016.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2016-01-07       Impact factor: 508.702

Review 5.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

6.  Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).

Authors:  Katsuhiko Uesaka; Narikazu Boku; Akira Fukutomi; Yukiyasu Okamura; Masaru Konishi; Ippei Matsumoto; Yuji Kaneoka; Yasuhiro Shimizu; Shoji Nakamori; Hirohiko Sakamoto; Soichiro Morinaga; Osamu Kainuma; Koji Imai; Naohiro Sata; Shoichi Hishinuma; Hitoshi Ojima; Ryuzo Yamaguchi; Satoshi Hirano; Takeshi Sudo; Yasuo Ohashi
Journal:  Lancet       Date:  2016-06-02       Impact factor: 79.321

7.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

8.  Preoperative C-Reactive Protein/Albumin Ratio Predicts Prognosis of Patients after Curative Resection for Gastric Cancer.

Authors:  Xuechao Liu; Xiaowei Sun; Jianjun Liu; Pengfei Kong; Shangxiang Chen; Youqing Zhan; Dazhi Xu
Journal:  Transl Oncol       Date:  2015-08       Impact factor: 4.243

9.  The impact of SPARC expression on the survival of pancreatic ductal adenocarcinoma patients after curative resection.

Authors:  Masaaki Murakawa; Toru Aoyama; Yohei Miyagi; Satoshi Kobayashi; Makoto Ueno; Manabu Morimoto; Masakatsu Numata; Naoto Yamamoto; Hiroshi Tamagawa; Norio Yukawa; Yasushi Rino; Munetaka Masuda; Soichiro Morinaga
Journal:  J Cancer       Date:  2019-01-01       Impact factor: 4.207

10.  The C-reactive protein/albumin ratio predicts overall survival of patients with advanced pancreatic cancer.

Authors:  Mengwan Wu; Jing Guo; Lihong Guo; Qiang Zuo
Journal:  Tumour Biol       Date:  2016-06-25
View more
  2 in total

1.  Clinical Implication of Preoperative C-Reactive Protein/Albumin Ratio in Malignant Transformation of Intraductal Papillary Mucinous Neoplasm: A Propensity Score Analysis.

Authors:  Hirotsugu Maruyama; Kojiro Tanoue; Yuki Ishikawa-Kakiya; Masafumi Yamamura; Akira Higashimori; Masaki Ominami; Yuji Nadatani; Shusei Fukunaga; Koji Otani; Shuhei Hosomi; Fumio Tanaka; Noriko Kamata; Yasuaki Nagami; Koichi Taira; Go Ohira; Kenjiro Kimura; Ryosuke Amano; Yasuhiro Fujiwara
Journal:  Diagnostics (Basel)       Date:  2022-02-21

2.  The prognostic value of fibrinogen to albumin ratio in malignant tumor patients: A meta-analysis.

Authors:  Baibei Li; Huachu Deng; Biao Lei; Leijie Chen; Xinyuan Zhang; Dingran Sha
Journal:  Front Oncol       Date:  2022-09-29       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.